Proteasome inhibitors: Poisons and remed
โ
Silke Meiners; Antje Ludwig; Verena Stangl; Karl Stangl
๐
Article
๐
2008
๐
John Wiley and Sons
๐
English
โ 470 KB
## Abstract The proteasome inhibitor bortezomib has been approved as a cytostatic drug for the therapy of multiple myeloma, and is currently being tested in clinical trials for a variety of other malignancies. At the same time, a growing number of animal studies suggest that proteasome inhibitors m